Research site

Ravenna 48121

4 studies enrolling now · 21 studies all time

What they study most

Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Advanced Solid Malignancies, Advanced Upper Gastrointestinal Tract Adenocarcinoma, Anemia, Cancer, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Higher-risk Myelodysplastic Syndromes, Lung Cancer, Lymphoma, Non-Hodgkin

Studies at this site

• Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab — Recruiting now
• Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression — Recruiting now
• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations — Recruiting now
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM — Recruiting now
• A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body — Running, not enrolling
• A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. — Running, not enrolling
• A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) — Running, not enrolling
• Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) — Running, not enrolling
• A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors — Running, not enrolling
• Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL — Running, not enrolling
• Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy — Completed
• Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL — Running, not enrolling
• Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC — Completed
• An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. — Completed
• Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy — Stopped early
• ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer — Completed
• Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab — Completed
• Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) — Stopped early
• Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes — Completed
• A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) — Completed
• Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications — Completed